Recent from talks
Hetero Drugs
Knowledge base stats:
Talk channels stats:
Members stats:
Hetero Drugs
Hetero Drugs is an Indian pharmaceutical company headquartered in Hyderabad and the world's largest producer of anti-retroviral drugs. Hetero's business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.
Hetero Group employs over 30,000 people and has operations in 145+ countries.
Hetero Group’s subsidiaries include Hetero Healthcare and Hetero Research Foundation, and also foreign subsidiaries such as Camber Pharmaceuticals in the United States and Southeast Asia, Amarox Pharma Global in Europe and GCC, and Seven Pharma in Latin America.
Hetero also operates Asia's Largest API SEZ manufacturing complex for APIs, with over 1000 reactors.
In 2009, as the swine flu outbreak was spreading across the globe and various health organizations and government agencies were piling up stocks of Oseltamivir as precautionary measures, Hetero supplied generic Oseltamivir under its brand name Fluvir.
Hetero delivered 10 million doses of Oseltamivir to the Indian government in 2009, and shipped about 80 million doses to over 60 countries. Hetero received its second order from Indian government to supply another 10 million doses of Oseltamivir later in 2009.
On 13 May 2020, Hetero entered a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of experimental COVID-19 drug ‘Remdesivir’ under the brand name Covifor in 127 countries, including India. On 29 July 2020, the company launched its version of the anti-viral drug Favipiravir under the brand name Favivir, after getting approval from Drugs Controller General of India (DCGI), used in the treatment of mild to moderate COVID-19 patients. On 26 August 2020, Hetero received authorization from the South African Health Products Regulatory Authority (SAHPRA) to import 'Remdesivir' in South Africa for the treatment for Covid-19. On 27 November 2020, Hetero Labs signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture 100 million doses of the Sputnik V vaccine.
Hetero is committed to achieving net zero emissions by 2045. They aim to reduce Scope 1 and Scope 2 carbon emissions by 25% by 2030 (baseline: 2022), increase their share of renewable energy to 30% by 2030, improve wastewater recycling by 5% each year, and achieve zero waste to landfill status by 2030. Hetero is a member of the UNGC and the SBTi and incorporates their sustainability initiatives and goals into their operations. Hetero has also received a silver medal rating from EcoVadis, placing it among the top 15% of companies globally for sustainability.
Hub AI
Hetero Drugs AI simulator
(@Hetero Drugs_simulator)
Hetero Drugs
Hetero Drugs is an Indian pharmaceutical company headquartered in Hyderabad and the world's largest producer of anti-retroviral drugs. Hetero's business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.
Hetero Group employs over 30,000 people and has operations in 145+ countries.
Hetero Group’s subsidiaries include Hetero Healthcare and Hetero Research Foundation, and also foreign subsidiaries such as Camber Pharmaceuticals in the United States and Southeast Asia, Amarox Pharma Global in Europe and GCC, and Seven Pharma in Latin America.
Hetero also operates Asia's Largest API SEZ manufacturing complex for APIs, with over 1000 reactors.
In 2009, as the swine flu outbreak was spreading across the globe and various health organizations and government agencies were piling up stocks of Oseltamivir as precautionary measures, Hetero supplied generic Oseltamivir under its brand name Fluvir.
Hetero delivered 10 million doses of Oseltamivir to the Indian government in 2009, and shipped about 80 million doses to over 60 countries. Hetero received its second order from Indian government to supply another 10 million doses of Oseltamivir later in 2009.
On 13 May 2020, Hetero entered a licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of experimental COVID-19 drug ‘Remdesivir’ under the brand name Covifor in 127 countries, including India. On 29 July 2020, the company launched its version of the anti-viral drug Favipiravir under the brand name Favivir, after getting approval from Drugs Controller General of India (DCGI), used in the treatment of mild to moderate COVID-19 patients. On 26 August 2020, Hetero received authorization from the South African Health Products Regulatory Authority (SAHPRA) to import 'Remdesivir' in South Africa for the treatment for Covid-19. On 27 November 2020, Hetero Labs signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture 100 million doses of the Sputnik V vaccine.
Hetero is committed to achieving net zero emissions by 2045. They aim to reduce Scope 1 and Scope 2 carbon emissions by 25% by 2030 (baseline: 2022), increase their share of renewable energy to 30% by 2030, improve wastewater recycling by 5% each year, and achieve zero waste to landfill status by 2030. Hetero is a member of the UNGC and the SBTi and incorporates their sustainability initiatives and goals into their operations. Hetero has also received a silver medal rating from EcoVadis, placing it among the top 15% of companies globally for sustainability.